Home2024 (Page 42)

Cardiol Therapeutics, a biotechnology company specializing in the research, development, and commercialization of anti-inflammatory therapies for heart diseases, recently announced its plans to advance CardiolRx into a late-stage trial in patients with recurrent pericarditis. This article explores the highlights of this strategic move, its impact